Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Influenza, Human 1Hematologic Diseases 1Agammaglobulinemia 1

Interventions

Rituximab 4Cyclophosphamide 4Etoposide 3Dexamethasone 3ponatinib 2pomalidomide 2fludarabine 2Whole-Body Irradiation 2Vincristine 2Sirolimus 2Prednisone 2Platelet Transfusion 2Mycophenolic Acid 2Lenalidomide 2Ifosfamide 2Doxorubicin 2Carboplatin 2Busulfan 2Brentuximab Vedotin 2Alemtuzumab 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2ricolinostat 1pembrolizumab 1nilotinib 1ibrutinib 1fludarabine phosphate 1epratuzumab 1daratumumab 1dacetuzumab 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hematologic Diseases × SARS-CoV-2 inactivated vaccines × Clear all
NCT01924169 2018-09-20

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Hematologic Diseases, Influenza, Human, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡